Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPV/r + TDF/FTC versus efavirenz + TDF/FTC in antiretroviral-naive HIV-1/HCV coinfected subjects
2005-001431-30Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lopinavir + ritonavir, efavirenz, tenofovir disoproxil fumarate and emtricitabine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Abbott Laboratories. Primary endpoints: Proportion of subjects with HIV-1 RNA below 50 copies/mL at Week 96 and Treatment-emergent adverse events. Started May 2005; status: terminated.
02
Drugs
lopinavir + ritonavirefavirenztenofovir disoproxil fumarateemtricitabine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-001431-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001431-30.